Braeburn Pharmaceuticals (PRIVATE.BRAEBURN)

Overall impact
B (79)

Commentary

Braeburn Pharmaceuticals is a strong overall performer. With a 'B' rating of 79.2 for overall impact (93rd percentile compared to all companies), Braeburn Pharmaceuticals ranks 63rd out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 59 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 519 others. On top material causes for Braeburn Pharmaceuticals's industry (Pharmaceuticals & Biotech), Braeburn Pharmaceuticals performs well in Child and Maternal Health (95.8 score), Reduced Use of tobacco (82.6), Decent, Safe Work Opportunities (95.1) and 5 other causes where it received an 'A' score and performs poorly in Accountable Institutions (25.8 score).
Impact
Cause PRIVATE.BRAEBURN
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2012
Employees
1,995
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Pennsylvania, United States
Share classes
PRIVATE.BRAEBURN
Description
Developer of medications intended for people living with the serious and fatal consequences of opioid use disorder. The company is committed to advancing a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, enabling patients, healthcare professionals and society to address the escalating disease burden of addiction.
Material causes
Ethos considers the following causes material for Braeburn Pharmaceuticals, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.